Abstract: A probiotic microcapsule for the treatment of reproductive tract infection and a preparation method and application thereof are provided. The probiotic microcapsule is obtained by coating probiotics with the coating material. The probiotics include one or several of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus crimpus, Lactobacillus brevis, Lactobacillus salivary, Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus bulgaricus. As probiotics screened in reproductive tract, it has high safety; It endows probiotics with adhesion function to ensure their effect in the reproductive tract; It overcomes the defects of current antibiotic therapy; It is expected to be used in a variety of reproductive tract infectious diseases.

Abstract: A transdermal double-layer microneedle based on hydrogen producing probiotics and its preparation method and application thereof are provided. The transdermal double-layer microneedle consists of a needle body and a backing layer. The raw material of the needle body includes hyaluronic acid and hyaluronidase. The raw material of the backing layer includes methacrylate anhydride gelatin and silk fibroin protein. The hydrogen producing bacteria are loaded in the microneedles, and the pore size of the matrix material is lower than the diameter of the probiotics, which will not lead to the leakage of bacteria and has high safety. Treatment of inflammatory skin diseases by gas has low side effects. The needle tip is loaded with hyaluronidase to increase the tissue space and improve the effect of gas treatment. It is expected to be used in psoriasis and other inflammatory skin diseases.

Abstract: The embodiment of the present disclosure provides a deep neural network (DNN)-based multi-target constant false alarm rate (CFAR) detection method. The method includes: obtaining target values to be measured based on radar IF (IF) signals to be detected, the target values to be measured including a measured frequency value and a measured intensity value of the radar IF signals; obtaining peak sequences based on the target values to be measured; generating a target detection result by processing the peak sequences based on a DNN detector, the DNN detector being a machine learning model; generating approximated maximum likelihood estimation (AMLE) of a scale parameter based on an approximated maximum likelihood estimator; generating a false alarm adjustment threshold based on a preset false alarm rate and the AMLE; and generating a constant false alarm detection result by processing the target detection result based on the false alarm adjustment threshold.

Abstract: The invention relates to the use of recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders, and methods of treating immune complex-mediated kidney disorders by administering such multimers.

Abstract: Disclosed is a multitarget constant false alarm rate detection method based on the signal proxy, which belongs to the technical field of radar constant false alarm rate detection. The method realizes target detection by utilizing the correlation between linear measurements of the radar intermediate frequency signal and the sensing matrix. To achieve a desired false alarm rate, the method determines the threshold by estimating the distributed parameters of the reduced sample set obtained by removing the detected targets from the original sample set. The method provided by the present disclosure can adapt to the sparsity of the signals, realize target detection without relying on the pre-estimated environmental background level, and effectively mitigate the multitarget shadowing effect.

Abstract: A method for preparing an aripiprazole type I microcrystal, including the following steps: dissolving aripiprazole in an acidifier, acquiring a medicament-having acid solution; adding an alkalizer while stirring, then adding water or aqueous ethanol 10 to 60 wt % while stirring, and separating by precipitation the aripiprazole type I microcrystal. Furthermore, a method for preparing a solid preparation having the aripiprazole type I microcrystal, an aripiprazole microcrystal having an average particle size of less than 20 ?m, and a solid preparation having the microcrystal. The method for preparing the aripiprazole type I microcrystal allows reduced pollution and loss, great safety, easy and convenient, reduced use of organic solvents, obviated need for demanding process conditions (such as cooling condition) and apparatus, low cost, and facilitated applicability in industrialized manufacturing.

Abstract: A method for preparing an aripiprazole type I microcrystal, including the following steps: dissolving aripiprazole in an acidifier, acquiring a medicament-having acid solution; adding an alkalizer while stirring, then adding water or aqueous ethanol 10 to 60 wt % while stirring, and separating by precipitation the aripiprazole type I microcrystal. Furthermore, a method for preparing a solid preparation having the aripiprazole type I microcrystal, an aripiprazole microcrystal having an average particle size of less than 24 ?m, and a solid preparation having the microcrystal. The method for preparing the aripiprazole type I microcrystal allows reduced pollution and loss, great safety, easy and convenient, reduced use of organic solvents, obviated need for demanding process conditions (such as cooling condition) and apparatus, low cost, and facilitated applicability in industrialized manufacturing.

Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide finction. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.

Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.

Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.

Abstract: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.